Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial – PubMed
NCT05008575 ( https://clinicaltrials.gov/study/NCT05008575 ).
Related Articles
Surgeon General Calls for Cancer Warning Label on Alcohol Products
Studies show alcohol consumption increases the risk of developing several types of cancer
National Cancer Institute comprehensive cancer centers: Significant improvement in mortality and symptom control, further opportunities remain toward health equity
The article by Thamm et al. reports that studies predominantly reported superior outcomes at comprehensive cancer centers (CCCs) compared to non CCCs in metrics related to…
Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL
Nirav N. Shah, MD, MSHP, details how BTK degraders could fill an unmet need in pretreated CLL/SLL and highlights promising data seen with NX-5948.
Sherko Kuemmel, MD on Final Survival Results From the WSG ADAPT-HR+/HER2-Negative Chemotherapy Trial
Presented by Sherko Kuemmel, MD, on December 12, 2024, at the San Antonio Breast Cancer Symposium The WSG ADAPT trial in patients with HR-positive, HER2-negative…
Epigenomic Platform Enhances Access to PSMA-Based Prostate Cancer Therapies
Jacob E. Berchuck, MD, discusses how a new epigenomic platform may influence the accessibility of PSMA-based therapies, especially for patients who may not have easy…
Blood Podcast | Blood | American Society of Hematology
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…
How I treat older patients with Ph/BCR-ABL–negative acute lymphoblastic leukemia
Edited by Associate Editor Hervé Dombret, this How I Treat series highlights the clinical approach to high-risk subgroups of acute lymphoblastic leukemia (
Best of 2024: Top Features From Cancer Therapy Advisor
This page includes links to Cancer Therapy Advisor’s top feature articles published in 2024.
Mount Sinai Researchers Identify Six-Gene Pattern to Predict Drug Success in Multiple Myeloma Patients
Genetic markers for venetoclax could help personalize treatment and improve outcomes